In today’s briefing:
- Classys (214150 KS): Bain Capital Deal Implies 11% Upside Potential
- Why Moderna And BioNTech Want To Boost Production Capacities In Africa?
Classys (214150 KS): Bain Capital Deal Implies 11% Upside Potential
- Classys (214150 KS) insiders have transferred 61% stake to private equity company Bain Capital for KRW670 billion. The deal values the shares at KRW17,000.
- Bain Capital has already invested in two beauty products companies in Korea. Both of the deals remained highly profitable for Bain. Classys is Bain’s third investment in the same space.
- Classys, with its differentiated and competitive products, is expanding its geographic presence. Consumables account for 49% of total revenue, thereby creating a stable and recurring revenue source for the company.
Why Moderna And BioNTech Want To Boost Production Capacities In Africa?
- Leading mRNA vaccine producers announced plans to build manufacturing facilities in Africa this year.
- According to Reuters, Rwanda, Senegal, or South Africa may be potential locations for Moderna’s new vaccine factory.
- Africa has the world’s lowest vaccination rate, and only ~5% of Africans are fully vaccinated today.
Before it’s here, it’s on Smartkarma
